{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:59:08Z","timestamp":1790229548069,"version":"4.1.0"},"reference-count":107,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:00:00Z","timestamp":1585180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>The CD38 antigen is expressed in several hematological malignancies, and the anti-CD38 monoclonal antibodies Daratumumab and Isatuximab have an established role in the therapy of multiple myeloma. However, data on the therapeutic utility of CD38 targeting in other lymphoid malignancies are limited. In chronic lymphocytic leukemia, the prognostic significance of CD38 expression is well accepted, and preclinical studies on the use of Daratumumab in monotherapy or combination therapy have demonstrated considerable efficacy. In other lymphoproliferative disorders, preclinical and clinical data have not been as compelling; however, CD38 overexpression likely contributes to resistance to checkpoint inhibitors, prompting numerous clinical trials in Hodgkin and non-Hodgkin lymphoma to investigate whether blocking CD38 enhances the efficacy of checkpoint inhibitors. Furthermore, due to its widespread expression in hematological tumors, CD38 represents an attractive target for cellular therapies such as CAR-T cells. The present review discusses current knowledge of CD38 expression and its implications in various lymphoid malignancies. Furthermore, it addresses current and future therapeutic perspectives, with a particular emphasis on the significance of CD38 interaction with immune cells of the tumor microenvironment. Lastly, results of ongoing studies using anti-CD38 antibodies will be reviewed.<\/jats:p>","DOI":"10.3390\/cells9040802","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T05:52:30Z","timestamp":1585720350000},"page":"802","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["The Many Facets of CD38 in Lymphoma: From Tumor\u2013Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy"],"prefix":"10.3390","volume":"9","author":[{"given":"Eleonora","family":"Calabretta","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Hematology, Humanitas Clinical and Research Center, Istituto di Ricovero e Cura a Carattere Scientifico, Rozzano, 20089 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3144-0124","authenticated-orcid":false,"given":"Carmelo","family":"Carlo-Stella","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Humanitas Clinical and Research Center, Istituto di Ricovero e Cura a Carattere Scientifico, Rozzano, 20089 Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Rozzano, 20089 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab plus lenalidomide and dexamethasone","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","article-title":"Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood-2019-02-895193","article-title":"A phase 1b study of isatuximab plus pomalidomide\/dexamethasone in relapsed\/refractory multiple myeloma","volume":"134","author":"Mikhael","year":"2019","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2016-09-740787","article-title":"A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2017","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2217\/fon-2017-0616","article-title":"Isatuximab plus pomalidomide\/dexamethasone versus pomalidomide\/dexamethasone in relapsed\/refractory multiple myeloma: ICARIA Phase III study design","volume":"14","author":"Richardson","year":"2018","journal-title":"Future Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1073\/pnas.77.3.1588","article-title":"Discrete stages of human intrathymic differentiation: Analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage","volume":"77","author":"Reinherz","year":"1980","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.4049\/jimmunol.160.3.1106","article-title":"Role of CD38 and its ligand in the regulation of MHC-nonrestricted cytotoxic T cells","volume":"160","author":"Cesano","year":"1998","journal-title":"J. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3389\/fimmu.2019.01187","article-title":"The Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases","volume":"10","author":"Hogan","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e26246","DOI":"10.4161\/onci.26246","article-title":"A CD38\/CD203a\/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes","volume":"2","author":"Horenstein","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2119\/molmed.2016.00198","article-title":"Adenosine Generated in the Bone Marrow Niche through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma","volume":"22","author":"Horenstein","year":"2016","journal-title":"Mol. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4049\/jimmunol.160.1.395","article-title":"Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member","volume":"160","author":"Deaglio","year":"1998","journal-title":"J. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1182\/blood-2004-10-3873","article-title":"CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival","volume":"105","author":"Deaglio","year":"2005","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.celrep.2017.01.007","article-title":"The Nuclear Receptor LXR Limits Bacterial Infection of Host Macrophages through a Mechanism that Impacts Cellular NAD Metabolism","volume":"18","author":"Matalonga","year":"2017","journal-title":"Cell Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.cmet.2016.05.006","article-title":"CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism","volume":"23","author":"Chini","year":"2016","journal-title":"Cell Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.cell.2013.11.037","article-title":"Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging","volume":"155","author":"Gomes","year":"2013","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1073\/pnas.1413493112","article-title":"Seminal CD38 is a pivotal regulator for fetomaternal tolerance","volume":"112","author":"Kim","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Patton, D.T., Wilson, M.D., Rowan, W.C., Soond, D.R., and Okkenhaug, K. (2011). The PI3K p110\u03b4 regulates expression of CD38 on regulatory T cells. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0017359"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","article-title":"Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma","volume":"23","author":"Feng","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_25","first-page":"173ra123","article-title":"CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation","volume":"5","author":"Bosma","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e12664","DOI":"10.1111\/sji.12664","article-title":"CD38 protein deficiency induces autoimmune characteristics and its activation enhances IL-10 production by regulatory B cells","volume":"87","year":"2018","journal-title":"Scand. J. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0092-8674(00)00139-2","article-title":"MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis","volume":"103","author":"Coussens","year":"2000","journal-title":"Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nm.2084","article-title":"Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth","volume":"16","author":"Houghton","year":"2010","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.imbio.2013.06.003","article-title":"Tumor associated macrophages and neutrophils in cancer","volume":"218","author":"Galdiero","year":"2013","journal-title":"Immunobiology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1126\/science.aaf7300","article-title":"CANCER. How neutrophils promote metastasis","volume":"352","year":"2016","journal-title":"Science"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1073\/pnas.0601335103","article-title":"Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis","volume":"103","author":"Bielekova","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"E231","DOI":"10.1073\/pnas.1206322110","article-title":"Natural killer cells promote immune tolerance by regulating inflammatory TH17 cells at the human maternal-fetal interface","volume":"110","author":"Fu","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"965","DOI":"10.4049\/jimmunol.1500591","article-title":"CD56brightCD16- NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+ T Cell Proliferation","volume":"195","author":"Morandi","year":"2015","journal-title":"J. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1158\/0008-5472.CAN-14-3639","article-title":"CD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer","volume":"75","author":"Karakasheva","year":"2015","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e97022","DOI":"10.1172\/jci.insight.97022","article-title":"CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients","volume":"3","author":"Karakasheva","year":"2018","journal-title":"JCI Insight"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2559.1994.tb00553.x","article-title":"Proliferation centres in B-cell malignant lymphoma, lymphocytic (B-CLL): An immunophenotypic study","volume":"24","author":"Schmid","year":"1994","journal-title":"Histopathology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2007-08-108605","article-title":"CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment","volume":"111","author":"Patten","year":"2008","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2002-06-1801","article-title":"The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression","volume":"101","author":"Ghia","year":"2003","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.V99.3.1023","article-title":"CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease","volume":"99","author":"Hamblin","year":"2002","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood.V98.1.181","article-title":"CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia","volume":"98","author":"Ibrahim","year":"2001","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1182\/blood.V98.9.2633","article-title":"Clinical significance of CD38 expression in chronic lymphocytic leukemia","volume":"98","author":"Maurillo","year":"2001","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1182\/blood-2002-04-1287","article-title":"Conversion of CD38 and\/or myeloid-associated marker expression status during the course of B-CLL: Association with a change to an aggressive clinical course","volume":"100","author":"Chang","year":"2002","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2003-11-3890","article-title":"CD38 on B-cell chronic lymphocytic leukemia cells has higher expression in lymph nodes than in peripheral blood or bone marrow","volume":"103","author":"Jaksic","year":"2004","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/leu.2010.36","article-title":"CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells","volume":"24","author":"Vaisitti","year":"2010","journal-title":"Leukemia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/leu.2011.369","article-title":"The CD49d\/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells","volume":"26","author":"Zucchetto","year":"2012","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2013.50.8515","article-title":"CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia","volume":"32","author":"Bulian","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/bjh.14647","article-title":"CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia","volume":"178","author":"Strati","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/bloodadvances.2017014506","article-title":"Calcium-RasGRP2-Rap1 signaling mediates CD38-induced migration of chronic lymphocytic leukemia cells","volume":"2","author":"Mele","year":"2018","journal-title":"Blood Adv."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1128\/MCB.20.6.1956-1969.2000","article-title":"Rap1 is a potent activation signal for leukocyte function-associated antigen 1 distinct from protein kinase C and phosphatidylinositol-3-OH kinase","volume":"20","author":"Katagiri","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004\u20132014: Sub-type analyses from the UK\u2019s Haematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","article-title":"Update on mantle cell lymphoma","volume":"132","author":"Maddocks","year":"2018","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/1078-0432.CCR-13-1077","article-title":"Distinction between asymptomatic monoclonal B-cell lymphocytosis with cyclin D1 overexpression and mantle cell lymphoma: From molecular profiling to flow cytometry","volume":"20","author":"Espinet","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1182\/blood-2002-06-1864","article-title":"A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease","volume":"101","author":"Orchard","year":"2003","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1182\/blood-2002-11-3456","article-title":"Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations","volume":"101","author":"Camacho","year":"2003","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood-2010-02-269514","article-title":"Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation","volume":"117","author":"Weniger","year":"2011","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1158\/0008-5472.CAN-08-4173","article-title":"CD38\/CD31, the CCL3 and CCL4 chemokines, and CD49d\/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival","volume":"69","author":"Zucchetto","year":"2009","journal-title":"Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.beha.2011.02.006","article-title":"Transformation of follicular lymphoma","volume":"24","author":"Lossos","year":"2011","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cyto.b.20477","article-title":"Flow cytometric evaluation of CD38 expression assists in distinguishing follicular hyperplasia from follicular lymphoma","volume":"76","author":"Mantei","year":"2009","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/ijc.28849","article-title":"Lymphoid neoplasm incidence by WHO subtype in Australia 1982\u20132006","volume":"135","author":"Turner","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.blre.2016.09.004","article-title":"High grade B-cell lymphoma with rearrangements of MYC and BCL2 and\/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma","volume":"31","author":"Rosenthal","year":"2017","journal-title":"Blood Rev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.clml.2018.12.013","article-title":"Phase 2 Study of Daratumumab in Relapsed\/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma","volume":"19","author":"Salles","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/cyto.b.21770","article-title":"Bright CD38 Expression by Flow Cytometric Analysis Is a Biomarker for Double\/Triple Hit Lymphomas with a Moderate Sensitivity and High Specificity","volume":"96","author":"Alsuwaidan","year":"2019","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_71","unstructured":"Sueoka, K., Yabushito, T., Maruota, H., Shimomura, Y., ONO, Y., Hiramoto, N., Yoshioka, S., Yonetoni, N., Matushita, A., and Hasmimoto, H. (2020, March 20). The High Expression of CD38 is Associated with Poor Prognosis in de Novo Diffuse Large B Cell Lymphoma. Available online: https:\/\/library.ehaweb.org\/eha\/2018\/stockholm\/214759\/kaoru.sueoka.the.high.expression.of.cd38.is.associated.with.poor.prognosis.in.html?f=media=1*listing=3*browseby=8."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00277-014-2044-x","article-title":"Flow cytometry CD4(+)CD26(-)CD38(+) lymphocyte subset in the microenvironment of Hodgkin lymphoma-affected lymph nodes","volume":"93","author":"Gasparetto","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/ajh.24571","article-title":"CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?","volume":"92","author":"Zaja","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1093\/annonc\/mdx316","article-title":"Beyond first-line non-anthracycline-based chemotherapy for extranodal NK\/T-cell lymphoma: Clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease","volume":"28","author":"Lim","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s00277-015-2359-2","article-title":"CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK\/T cell lymphoma, nasal type","volume":"94","author":"Wang","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJMc1605684","article-title":"Targeting CD38 in Refractory Extranodal Natural Killer Cell-T-Cell Lymphoma","volume":"375","author":"Hari","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"Tai","year":"2011","journal-title":"J. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.1501351","article-title":"The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fc\u03b3 Receptor-Mediated Cross-Linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1182\/blood-2011-06-275610","article-title":"CD38 and chronic lymphocytic leukemia: A decade later","volume":"118","author":"Malavasi","year":"2011","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1158\/1078-0432.CCR-15-2095","article-title":"The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia","volume":"23","author":"Rodriguez","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1158\/1078-0432.CCR-18-3412","article-title":"Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia","volume":"25","author":"Manna","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Vidal-Crespo, A., Matas-C\u00e9spedes, A., Rodriguez, V., Rossi, C., Valero, J.G., Serrat, N., Sanjuan Pla, A., Men\u00e9ndez, P., Rou\u00e9, G., and L\u00f3pez-Guillermo, A. (2019). Daratumumab displays in vitro and in vivo anti-tumor activity in models of B cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. Haematologica, in press.","DOI":"10.3324\/haematol.2018.211904"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood-2019-123446","article-title":"Daratumumab Monotherapy for Patients with Relapsed or Refractory (R\/R) Natural Killer\/T-cell Lymphoma (NKTCL), Nasal type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study","volume":"134","author":"Huang","year":"2019","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/2159-8290.CD-17-1033","article-title":"CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1\/PD-L1 Blockade","volume":"8","author":"Chen","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"25602","DOI":"10.18632\/oncotarget.4693","article-title":"A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation","volume":"6","author":"Morandi","year":"2015","journal-title":"Oncotarget"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed\/Refractory Classic Hodgkin Lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab Combined With Brentuximab Vedotin for Relapsed\/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study","volume":"37","author":"Zinzani","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11912-019-0789-z","article-title":"Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma","volume":"21","author":"Strati","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/CJI.0b013e3181adaff1","article-title":"Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma","volume":"32","author":"Mihara","year":"2009","journal-title":"J. Immunother."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1038\/bcj.2012.21","article-title":"T-cell immunotherapy with a chimeric receptor against CD38 is effective in eradicating chemotherapy-resistant B-cell lymphoma cells overexpressing survivin induced by BMI-1","volume":"2","author":"Bhattacharyya","year":"2012","journal-title":"Blood Cancer J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-017-0488-x","article-title":"T cells bearing anti-CD19 and\/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells","volume":"10","author":"Mihara","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Dombret","year":"2018","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab for Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1158\/1078-0432.CCR-18-2752","article-title":"Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38\/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release","volume":"25","author":"Fajardo","year":"2019","journal-title":"Clin. Cancer Res."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/4\/802\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:11:56Z","timestamp":1760173916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/4\/802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,26]]},"references-count":107,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["cells9040802"],"URL":"https:\/\/doi.org\/10.3390\/cells9040802","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,26]]}}}